Local Tech Wire

MORRISVILLE, N.C. – (Nasdaq: SLXP) is seeking approval from the U.S. Food and Drug Administration for the use of its drug Xifaxan to treat non-constipation irritable bowel syndrome.

Xifaxan is already sold as a treatment for traveler’s diarrhea.

According to Salix, the FDA has 60 days to respond to the application.

Get the latest news alerts: at Twitter.